Currently Viewing:
Newsroom
Currently Reading
Venclexta/Venclyxto Effective in Treating Chronic Lymphocytic Leukemia
June 27, 2017 – Alison Rodriguez
Understanding Stakeholder Objectives, and Aligning Them, in Cancer Care
June 26, 2017 – Surabhi Dangi-Garimella, PhD
Diagnostic Immunoassays Could Spare Patients High-Risk Pancreatic Resection
June 25, 2017 – Surabhi Dangi-Garimella, PhD
US Multi-Society Task Force's New Colorectal Cancer Screening Recommendations
June 25, 2017 – Alison Rodriguez
FDA Approves Rituxan Hycela for Treating Certain Blood Cancers
June 24, 2017 – Alison Rodriguez
Genentech's Ocrevus Reduces Disease Progression in Multiple Sclerosis Patients
June 23, 2017 – Alison Rodriguez
FDA Approves of Darzalex Combination for Multiple Myeloma
June 23, 2017 – Alison Rodriguez
Family History, Mutation Location Increase Risks of Breast, Ovarian Cancers
June 23, 2017 – Alison Rodriguez
Dr Yousuf Zafar of Duke Cancer Institute Joins The Samfund's Advisory Council
June 22, 2017 – AJMC Staff

Venclexta/Venclyxto Effective in Treating Chronic Lymphocytic Leukemia

Alison Rodriguez
Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia, according to Roche.
Data from multiple studies have demonstrated the efficacy of Venclexta/Venclyxto in treating relapsed or refractory chronic lymphocytic leukemia (CLL), according to Roche.

Venclexta/Venclyxto is a small molecule intended to bind and inhibit the BCL-2 protein, a protein that often resists therapies. Through blocking BCL-2, researchers intend for cancer cells to be signaled to self-destruct.

The studies included a high-risk population, however, safety profiles and high response rates received among CLL patients reached 79% with the utilization of Venclexta/Venclyxto. In addition to CLL treatment, data from phase Ib revealed the anti-cancer activity of Venclexta/Venclyxto in other blood cancers, including acute myeloid leukemia and relapsed or refractory multiple myeloma, indicating the future potential of the drug.

“Confirmation that Venclexta/Venclyxto achieves a high response rate in relapsed or refractory chronic lymphocytic leukemia in people with 17p deletion is very promising, as these patients have a particularly poor prognosis,” Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development, said in a statement.

Roche and AbbVie, Venclexta/Venclyxto’s co-developer, plan to continue research within phase III clinical trials for CLL treatment, as well as developing new studies to research Venclexta/Venclyxto’s efficacy in the treating other blood cancers.

“We are also pleased to see early data highlighting the potential central role of BCL-2 in other difficult-to-treat blood cancers and look forward to validating these results in further studies,” concluded Horning.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up